Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s238, 2023. DOI: 10.25251/skin.7.supp.238. Disponível em: https://skin.dermsquared.com/skin/article/view/2355. Acesso em: 30 apr. 2026.